Phio Pharmaceuticals Corp. (PHIO)
NASDAQ: PHIO · Real-Time Price · USD
1.220
-0.070 (-5.43%)
At close: Feb 12, 2026, 4:00 PM EST
1.250
+0.030 (2.46%)
After-hours: Feb 12, 2026, 7:59 PM EST
Phio Pharmaceuticals Employees
Phio Pharmaceuticals had 5 employees as of December 31, 2024. The number of employees decreased by 4 or -44.44% compared to the previous year.
Employees
5
Change (1Y)
-4
Growth (1Y)
-44.44%
Revenue / Employee
n/a
Profits / Employee
-$1,590,600
Market Cap
13.13M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 5 | -4 | -44.44% | 5 | 0 |
| Dec 31, 2023 | 9 | -1 | -10.00% | 8 | 1 |
| Dec 31, 2022 | 10 | -2 | -16.67% | 9 | 1 |
| Dec 31, 2021 | 12 | 2 | 20.00% | 12 | 0 |
| Dec 31, 2020 | 10 | -1 | -9.09% | 10 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 61 |
| Curis | 34 |
| BioCardia | 20 |
| NewcelX | 15 |
| Cellectar Biosciences | 11 |
| Cocrystal Pharma | 11 |
| Cadrenal Therapeutics | 4 |
| Hoth Therapeutics | 3 |
PHIO News
- 17 hours ago - What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday? - Benzinga
- 2 days ago - Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients - Benzinga
- 2 days ago - Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial - Newsfile Corp
- 17 days ago - Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference - Newsfile Corp
- 23 days ago - Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial - Newsfile Corp
- 4 weeks ago - Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026 - Newsfile Corp
- 7 weeks ago - Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762 - Newsfile Corp
- 2 months ago - Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762 - Newsfile Corp